Novartis Ag (NVS) Non-Current Receivables (2017 - 2025)

Novartis Ag's Non-Current Receivables history runs 9 years deep, the most recent figure standing at $403.0 million for Q4 2025.

• In Q4 2025, Non-Current Receivables rose 125.14% year-over-year to $403.0 million; the TTM figure through Dec 2025 stood at $403.0 million (up 125.14% YoY), while the FY2025 annual figure was $403.0 million, up 125.14% from the prior year.
• Non-Current Receivables came in at $403.0 million for Q4 2025 at Novartis Ag, up from $179.0 million in the prior quarter.
• In the past five years, Non-Current Receivables ranged from a high of $403.0 million in Q4 2025 to a low of $179.0 million in Q4 2024.
• A 5-year average of $235.4 million and a median of $197.0 million in 2022 frame the typical range for Non-Current Receivables.
• Across the five-year window, Non-Current Receivables slipped 16.36% in 2024 and soared 125.14% in 2025, its largest moves.
• Novartis Ag's Non-Current Receivables stood at $184.0 million in 2021, then gained by 7.07% to $197.0 million in 2022, then advanced by 8.63% to $214.0 million in 2023, then declined by 16.36% to $179.0 million in 2024, then jumped by 125.14% to $403.0 million in 2025.
• According to Business Quant data, Non-Current Receivables over the past three periods registered $403.0 million, $179.0 million, and $214.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison